M orbidity and mortality rates in patients with Staphylococcus aureus bacteremia remain high even though diagnostic tests have improved and antibiotic therapy is effective. Diagnosis and management are made more complex by diffi culties in fi nding the source of bacteremia and sites of metastatic infection.
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S aureus bacteremia is a fi nding that demands further investigation, since up to 25% of people who have it may have endocarditis, a condition with even worse consequences. 1 The ability of S aureus to infect normal valves 2, 3 adds to the challenge. In the mid20th century, Wilson and Hamburger 4 demonstrated that 64% of patients with S aureus bacteremia had evidence of valvular infection at autopsy. In a more recent case series of patients with S aureus endocarditis, the diagnosis was established at autopsy in 32%. 5 Specifi c clinical fi ndings in patients with complicated S aureus bacteremia-those who have a site of infection remote from or extended beyond the primary focus-may be useful in determining the need for additional diagnostic and therapeutic measures.
In a prospective cohort study, Fowler et al 6 identifi ed several factors that predicted complicated S aureus bacteremia (including but not limited to endocarditis):
• Prolonged bacteremia (> 48-72 hours after initiation of therapy) • Community onset • Fever persisting more than 72 hours • Skin fi ndings suggesting systemic infection.
■ THE ROLE OF ECHOCARDIOGRAPHY
Infective endocarditis may be diffi cult to detect in patients with S aureus bacteremia; experts recommend routine use of echocardiography in this process. 7, 8 Transesophageal echocardiography (TEE) detects more cases of endocarditis than transthoracic echocardiography (TTE), 9,10 but access, cost, and risks lead to questions about its utility.
Guidance for the use of echocardiography in S aureus bacteremia 1,10-14 continues to evolve. Consensus seems to be emerging that the risk of endocarditis is lower in patients with S aureus bacteremia who: Heriot et al 14 point out that studies of riskstratifi cation approaches to echocardiography in patients with S aureus bacteremia are difficult to interpret, as there are questions regarding the validity of the studies and the balance of the risks and benefi ts. 1 The question of timing of TEE remains largely unexplored, both in initial screening and in follow-up of previously undiagnosed cases of S aureus endocarditis.
In BACTEREMIA low pretest probability for infectious endocarditis and in patients with a disease focus that requires extended treatment are derived from a survey of infectious disease physicians. 16 
■ ROLE OF INFECTIOUS DISEASE CONSULTATION
Infectious disease consultation reduces mortality rates and healthcare costs for a variety of infections, with endocarditis as a prime example. 17 For S aureus bacteremia, a large and growing body of literature demonstrates the impact of infectious disease consultation, including improved adherence to guidelines and quality measures, [18] [19] [20] lower in-hospital mortality rates [18] [19] [20] [21] and earlier hospital discharge. 18 In the era of "curbside consults" and "e-consultation," it is interesting to note the enduring value of bedside, in-person consultation in the management of S aureus bacteremia. 20 Many people with S aureus bacteremia should undergo TEE. Until the evidence becomes more robust, the decision to forgo TEE must be made with caution. The expertise of infectious disease physicians in the diagnosis and management of endocarditis can assist clinicians working with the often-complex patients who develop S aureus bacteremia. If the goal is to improve outcomes, infectious disease consultation may be at least as important as appropriate selection of patients for TEE.
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